文献速递造血干细胞移植与细胞治疗

成人噬血细胞性淋巴组织细胞增多症患者异基因移植后结局良好

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis.
PubMed 文献 · Blood Adv · 2023-01-01

该研究分析2010年起在Dana-Farber癌症研究所接受移植的成人噬血细胞性淋巴组织细胞增多症(HLH)患者,均采用含早期阿仑单抗的减低强度预处理方案。3年总生存率75%(95%CI 51-89),无进展生存率71%(95%CI 46-86),3年累积复发率15%(95%CI 3.4-33),非复发死亡率15%(95%CI 3.5-34)。

要点

  • 全部患者均实现植入,3年总生存率75%(95%CI 51-89)。
  • 3年累积复发率15%(95%CI 3.4-33),无孤立HLH复发不伴恶性肿瘤复发。
  • 混合嵌合常见但与移植结局不相关,感染和GVHD与本院标准减低强度预处理移植相当。

核心结论

  • 数据提示,采用含早期阿仑单抗预处理的减低强度方案进行异基因移植可消除HLH的免疫缺陷,为该难治疾病提供潜在治愈选择。

研究设计与样本

  • 分析2010年起在Dana-Farber癌症研究所接受移植的成人HLH患者移植结局。
  • 患者统一采用减低强度预处理平台,包含早期给予阿仑单抗及标准感染和移植物抗宿主病(GVHD)预防。

主要发现

  • 全部患者均记录到植入。
  • 移植后3年总生存率为75%(95%CI 51-89),3年无进展生存率为71%(95%CI 46-86)。
  • 3年累积复发率为15%(95%CI 3.4-33),无孤立HLH复发不伴恶性肿瘤复发。
  • 3年非复发死亡累积发生率为15%(95%CI 3.5-34)。
  • 感染并发症和GVHD结局与本研究所标准减低强度预处理(RIC)移植相当,混合嵌合常见但与移植结局不相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome marked by a severe hyperinflammatory state characterized by aberrant T- and natural killer-cell activity leading to prolonged hypercytokinemia and can be rapidly fatal if not diagnosed and treated early. While upfront therapy is aimed at reducing hyperinflammation and controlling possible triggers, allogeneic hematopoietic stem cell transplantation (HSCT) is indicated for primary and relapsed/refractory cases to attain sustained remission. While this has been explored extensively in the pediatric population, there are limited data on adults undergoing HSCT for HLH. We analyzed transplant outcomes in an adult HLH population in the modern era who were transplanted at Dana-Farber Cancer Institute from 2010 onwards. Patients were uniformly transplanted on a reduced intensity platform incorporating early administration of alemtuzumab with standard infectious and graft-versus-host disease (GVHD) prophylaxis. Engraftment was documented for all patients. At 3 years after transplantation, overall survival (OS) was 75% (95% confidence interval [CI], 51-89) while 3-year progression-free survival (PFS) was 71% (95% CI, 46-86). The 3-year cumulative incidence of relapse was 15% (95% CI, 3.4-33). There were no isolated HLH relapses without relapse of malignancy. The cumulative incidence of nonrelapse mortality at 3 years was 15% (95% CI, 3.5-34). Infectious complications and GVHD outcomes were comparable to standard reduced-intensity conditioning (RIC) transplantation at our institute. Mixed chimerism was common but did not correlate with transplant outcomes. Our data suggest that the immune defect in HLH can be abrogated with allogeneic transplantation using a reduced intensity regimen with early administration of alemtuzumab as preconditioning, providing a potentially curative option for this difficult disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gooptu M, Kim HT, Jacobsen E, et al. Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2023. PMID: 35439287. doi:10.1182/bloodadvances.2022007012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。